Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry
Identifieur interne : 001768 ( Main/Curation ); précédent : 001767; suivant : 001769Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry
Auteurs : Kandatege Wimalasena [États-Unis]Source :
- Medicinal Research Reviews [ 0198-6325 ] ; 2011-07.
English descriptors
- KwdEn :
Abstract
Vesicular monoamine transporters (VMAT) are responsible for the uptake of cytosolic monoamines into synaptic vesicles in monoaminergic neurons. Two closely related VMATs with distinct pharmacological properties and tissue distributions have been characterized. VMAT1 is preferentially expressed in neuroendocrine cells and VMAT2 is primarily expressed in the CNS. The neurotoxicity and addictive properties of various psychostimulants have been attributed, at least partly, to their interference with VMAT2 functions. The quantitative assessment of the VMAT2 density by PET scanning has been clinically useful for early diagnosis and monitoring of the progression of Parkinson's and Alzheimer's diseases and drug addiction. The classical VMAT2 inhibitor, tetrabenazine, has long been used for the treatment of chorea associated with Huntington's disease in the United Kingdom, Canada, and Australia, and recently approved in the United States. The VMAT2 imaging may also be useful for exploiting the onset of diabetes mellitus, as VMAT2 is also expressed in the β‐cells of the pancreas. VMAT1 gene SLC18A1 is a locus with strong evidence of linkage with schizophrenia and, thus, the polymorphic forms of the VMAT1 gene may confer susceptibility to schizophrenia. This review summarizes the current understanding of the structure–function relationships of VMAT2, and the role of VMAT2 on addiction and psychostimulant‐induced neurotoxicity, and the therapeutic and diagnostic applications of specific VMAT2 ligands. The evidence for the linkage of VMAT1 gene with schizophrenia and bipolar disorder I is also discussed. © 2010 Wiley Periodicals, Inc. Med Res Rev 31: 483‐519, 2011
Url:
DOI: 10.1002/med.20187
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001389
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001389
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000351
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001844
Links to Exploration step
ISTEX:A174C413E6726EA8D185183D9624D28B4359702ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry</title><author><name sortKey="Wimalasena, Kandatege" sort="Wimalasena, Kandatege" uniqKey="Wimalasena K" first="Kandatege" last="Wimalasena">Kandatege Wimalasena</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A174C413E6726EA8D185183D9624D28B4359702A</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/med.20187</idno><idno type="url">https://api-v5.istex.fr/document/A174C413E6726EA8D185183D9624D28B4359702A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001389</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001389</idno><idno type="wicri:Area/Istex/Curation">001389</idno><idno type="wicri:Area/Istex/Checkpoint">000351</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000351</idno><idno type="wicri:doubleKey">0198-6325:2011:Wimalasena K:vesicular:monoamine:transporters</idno><idno type="wicri:Area/Main/Merge">001844</idno><idno type="wicri:Area/Main/Curation">001768</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry</title><author><name sortKey="Wimalasena, Kandatege" sort="Wimalasena, Kandatege" uniqKey="Wimalasena K" first="Kandatege" last="Wimalasena">Kandatege Wimalasena</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Kansas</region></placeName><wicri:cityArea>Department of Chemistry, Wichita State University, Wichita</wicri:cityArea></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Medicinal Research Reviews</title><title level="j" type="abbrev">Med. Res. Rev.</title><idno type="ISSN">0198-6325</idno><idno type="eISSN">1098-1128</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-07">2011-07</date><biblScope unit="volume">31</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="483">483</biblScope><biblScope unit="page" to="519">519</biblScope></imprint><idno type="ISSN">0198-6325</idno></series><idno type="istex">A174C413E6726EA8D185183D9624D28B4359702A</idno><idno type="DOI">10.1002/med.20187</idno><idno type="ArticleID">MED20187</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0198-6325</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>catecholamine metabolism</term><term>oxidative stress</term><term>psychostimulant abuse</term><term>synaptic vesicles</term><term>vesicular monoamine transporter 1 (VMAT1)</term><term>vesicular monoamine transporter 2 (VMAT2)</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Vesicular monoamine transporters (VMAT) are responsible for the uptake of cytosolic monoamines into synaptic vesicles in monoaminergic neurons. Two closely related VMATs with distinct pharmacological properties and tissue distributions have been characterized. VMAT1 is preferentially expressed in neuroendocrine cells and VMAT2 is primarily expressed in the CNS. The neurotoxicity and addictive properties of various psychostimulants have been attributed, at least partly, to their interference with VMAT2 functions. The quantitative assessment of the VMAT2 density by PET scanning has been clinically useful for early diagnosis and monitoring of the progression of Parkinson's and Alzheimer's diseases and drug addiction. The classical VMAT2 inhibitor, tetrabenazine, has long been used for the treatment of chorea associated with Huntington's disease in the United Kingdom, Canada, and Australia, and recently approved in the United States. The VMAT2 imaging may also be useful for exploiting the onset of diabetes mellitus, as VMAT2 is also expressed in the β‐cells of the pancreas. VMAT1 gene SLC18A1 is a locus with strong evidence of linkage with schizophrenia and, thus, the polymorphic forms of the VMAT1 gene may confer susceptibility to schizophrenia. This review summarizes the current understanding of the structure–function relationships of VMAT2, and the role of VMAT2 on addiction and psychostimulant‐induced neurotoxicity, and the therapeutic and diagnostic applications of specific VMAT2 ligands. The evidence for the linkage of VMAT1 gene with schizophrenia and bipolar disorder I is also discussed. © 2010 Wiley Periodicals, Inc. Med Res Rev 31: 483‐519, 2011</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001768 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001768 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:A174C413E6726EA8D185183D9624D28B4359702A
|texte= Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry
}}
| This area was generated with Dilib version V0.6.29. |  |